Sulfateq BV is an innovative biotechnology research company that is developing breakthrough compounds for the prevention of Acute Kidney Injury (AKI). Our compounds emerged from research on hibernation and provide a new mechanism of action for cell protection, organ protection and prophylactic use and they have a huge potential to support drug development for AKI prevention.


Why hibernation?

We are inspired by the principles of hibernation. During hibernation mamals protect their body against threatening conditions. Our research has proved that hibernation can also be used for protecting cells, organs an organisms. That is why we use its natural protection process against cooling and rewarming to develop therapeutic applications.


A direct application of our compounds is protecting organs and body during major surgeries. Acute Kidney Injury (AKI) can occur during various medical operations, one of which is cardiac surgery. We regard this medical need as the most direct opportunity for the application of SUL-compounds as a medical prophylactic treatment.

Investment opportunity

There is no therapy available for kidney protection, or organ protection in general, during major surgery. With our SUL-138 compound we can change this. To advance the clinical development we are seeking investors who we can offer a high-profit business model with high-potential opportunities focussing on pharmaceutical blockbuster markets.

Meet Our Team

Kees van der Graaf

Kees van der Graaf

President & CEO

Serial entrepreneur specialized in the start-up of prospering companies / products in the pharmaceutical and biotechnological field

Guido Krenning

Guido Krenning


Passionate researcher with extensive knowledge about the cardiovascular system, tissue engineering and molecular biology.

André Goossens

André Goossens


Financial expert with vast international experience. His main expertise lies in corporate and financial management.

Pieter Vogelaar

Pieter Vogelaar


Eager scientist developing models to unravel the mechanism behind the protective effects of SUL-compounds.

Recent posts

SNN Valorisation grant for Sulfateq B.V.

We are proud to announce that Sulfateq B.V. received a Samenwerkingsverband Noord-Nederland (SNN) Valorisation grant for the development of SUL-138 as Acute Kidney Injury (AKI) prophylaxis. This grant helps us to continue the development that was already stimulated by...

New Paper about SUL-109

There is a new manuscript available which describes the positive effect of our SUL-109 compound which is commercially available as our ROKEPIE preservation solution. This article was written by Fatima Aerts from the Hacettepe University in Ankara (Turkey). You can...

Winterslaap voor de mens

In de zomer keihard doorgaan, en zodra het koud wordt, even de boel de boel laten. Rust. Voor velen aanlokkelijk, maar het lijkt nog toekomstmuziek. Professor Rob Henning (Rijksuniversiteit Groningen) scientific board van Sulfateq, denkt dat het in de toekomst...


We offer a great opportunity for investing in a breakthrough solution for the prevention of Acute Kidney Injury. If you share the same enthusiasm for the possibilities of hibernation in healthcare and its huge potential, please contact us for more information about investment possibilities or fill in our contact form and we will contact you as soon as possible. We are looking forward doing business with you!